Particularly NT15799 led to the irreversible IRS-1/2 protein elimination and cell growth inhibition in melanoma cells.98 Additional studies have confirmed the pharmacological effect of NT157 in osteosarcoma100 and prostate cancer.101 Although the therapeutic activity of NT157 against breast cancer has been discussed in several meetings, no clinical data have yet been published. This evidence concerns the gene IRS1 and breast carcinoma.